Cargando…

KRAS mutation effects on the 2-[18F]FDG PET uptake of colorectal adenocarcinoma metastases in the liver

BACKGROUND: Deriving individual tumor genomic characteristics from patient imaging analysis is desirable. We explore the predictive value of 2-[18F]FDG uptake with regard to the KRAS mutational status of colorectal adenocarcinoma liver metastases (CLM). METHODS: 2-[18F]FDG PET/CT images, surgical pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Popovic, M., Talarico, O., van den Hoff, J., Kunin, H., Zhang, Z., Lafontaine, D., Dogan, S., Leung, J., Kaye, E., Czmielewski, C., Mayerhoefer, M. E., Zanzonico, P., Yaeger, R., Schöder, H., Humm, J. L., Solomon, S. B., Sofocleous, C. T., Kirov, A. S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683631/ https://www.ncbi.nlm.nih.gov/pubmed/33226505 http://dx.doi.org/10.1186/s13550-020-00707-0

Ejemplares similares

Comparison of FDG and FMISO uptakes and distributions in head and neck squamous cell cancer tumors
por: Nehmeh, Sadek A., et al.
Publicado: (2021)

TriDFusion (3DF) image viewer
por: Lafontaine, Daniel, et al.
Publicado: (2022)

[18F]FDG-PET/CT Radiomics for Prediction of Bone Marrow Involvement in Mantle Cell Lymphoma: A Retrospective Study in 97 Patients
por: Mayerhoefer, Marius E., et al.
Publicado: (2020)

Reproducibility of (18)F-fluoromisonidazole intratumour distribution in non-small cell lung cancer
por: Grkovski, Milan, et al.
Publicado: (2016)

Kras mutation is a marker of worse oncologic outcomes after percutaneous radiofrequency ablation of colorectal liver metastases
por: Shady, Waleed, et al.
Publicado: (2017)

3D margin assessment predicts local tumor progression after ablation of colorectal cancer liver metastases
por: Kamarinos, Nikiforos Vasiniotis, et al.
Publicado: (2022)

SUV(fdg): A standard-uptake-value (SUV) body habitus normalizer specific to fluorodeoxyglucose (FDG) in humans
por: Beattie, Bradley J., et al.
Publicado: (2022)

PI3K pathway mutations are associated with longer time to local progression after radioembolization of colorectal liver metastases
por: Ziv, Etay, et al.
Publicado: (2017)

MRI and PET/MRI in hematologic malignancies
por: Mayerhoefer, Marius E., et al.
Publicado: (2019)

Real-Time Split-Dose PET/CT-Guided Ablation Improves Colorectal Liver Metastasis Detection and Ablation Zone Margin Assessments without the Need for Repeated Contrast Injection
por: Zirakchian Zadeh, Mahdi, et al.
Publicado: (2022)

The Prognostic Value of (18)F-FDG PET/CT and KRAS Mutation in Colorectal Cancers
por: Arslan, Esra, et al.
Publicado: (2020)

Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma
por: Mayerhoefer, Marius E., et al.
Publicado: (2019)

Is there a reliable size cut-off for splenic involvement in lymphoma? A [18F]FDG-PET controlled study
por: Berzaczy, Dominik, et al.
Publicado: (2019)

Correlations among KRAS Mutation, Microsatellite Instability, and (18)F-FDG Uptake in Colon Cancer
por: Lee, Sun Seong, et al.
Publicado: (2022)

(18)F-Fluciclovine ((18)F-FACBC) PET imaging of recurrent brain tumors
por: Michaud, Laure, et al.
Publicado: (2019)

Prediction of EGFR and KRAS mutation in non-small cell lung cancer using quantitative (18)F FDG-PET/CT metrics
por: Minamimoto, Ryogo, et al.
Publicado: (2017)

Radiation dosimetry of 18F-FDG PET/CT: incorporating exam-specific parameters in dose estimates
por: Quinn, Brian, et al.
Publicado: (2016)

MLTI-02. A PHASE I TRIAL OF SORAFENIB WITH WHOLE BRAIN RADIOTHERAPY (WBRT) IN BREAST CANCER PATIENTS WITH BRAIN METASTASES AND A CORRELATIVE FLT-PET BRAIN IMAGING STUDY IN PATIENTS RECEIVING WBRT +/- SORAFENIB
por: Morikawa, Aki, et al.
Publicado: (2019)

Pilot study of PET imaging of (124)I-iodoazomycin galactopyranoside (IAZGP), a putative hypoxia imaging agent, in patients with colorectal cancer and head and neck cancer
por: O’Donoghue, Joseph A, et al.
Publicado: (2013)

FDG PET/CT imaging features and clinical utility in COVID-19
por: Yeh, Randy, et al.
Publicado: (2021)

Patient-adapted organ absorbed dose and effective dose estimates in pediatric 18F-FDG positron emission tomography/computed tomography studies
por: Quinn, Brian M., et al.
Publicado: (2020)

Prognostic model using (18)F-FDG PET radiomics predicts progression-free survival in relapsed/refractory Hodgkin lymphoma
por: Driessen, Julia, et al.
Publicado: (2023)

Correlation of EGFR or KRAS mutation status with (18)F-FDG uptake on PET-CT scan in lung adenocarcinoma
por: Takamochi, Kazuya, et al.
Publicado: (2017)

Association between KRAS mutation and lung metastasis in advanced colorectal cancer
por: Pereira, A A L, et al.
Publicado: (2015)

RECIL Versus Lugano for Treatment Response Assessment in FDG-Avid Non-Hodgkin Lymphomas: A Head-to-Head Comparison in 54 Patients
por: Berzaczy, Dominik, et al.
Publicado: (2019)

Added value of quantitative, multiparametric 18F-FDG PET/MRI in the locoregional staging of rectal cancer
por: Herold, Alexander, et al.
Publicado: (2022)

Evaluation of [18F]-FDG-Based Hybrid Imaging Combinations for Assessment of Bone Marrow Involvement in Lymphoma at Initial Staging
por: Asenbaum, Ulrika, et al.
Publicado: (2016)

Baseline (18)F-FDG PET/CT Radiomics in Classical Hodgkin’s Lymphoma: The Predictive Role of the Largest and the Hottest Lesions
por: Triumbari, Elizabeth Katherine Anna, et al.
Publicado: (2023)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

Colorectal Cancer Liver Metastases: Genomics and Biomarkers with Focus on Local Therapies
por: Kitsel, Yuliya, et al.
Publicado: (2023)

Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome
por: Lemstrova, Radmila, et al.
Publicado: (2017)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

KRAS mutation in colorectal cancer metastases after adjuvant FOLFOX for the primary
por: Vauthey, J-N, et al.
Publicado: (2012)

Preoperative metabolic tumor volume of intrahepatic cholangiocarcinoma measured by (18)F-FDG-PET is associated with the KRAS mutation status and prognosis
por: Ikeno, Yoshinobu, et al.
Publicado: (2018)

Pretreatment (18)F-FDG PET/CT Imaging Predicts the KRAS/NRAS/BRAF Gene Mutational Status in Colorectal Cancer
por: He, Peng, et al.
Publicado: (2021)

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2020)

FDG PET Appearance of “Cannonball” Pulmonary Metastases
por: Meka, Murali, et al.
Publicado: (2015)

BCL-X(L) PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRAS(G12C)-mutated cancers
por: Khan, Sajid, et al.
Publicado: (2022)

The origins and genetic interactions of KRAS mutations are allele- and tissue-specific
por: Cook, Joshua H., et al.
Publicado: (2021)

Reply: KRAS mutation in colorectal cancer metastases after adjuvant folfox for the primary
por: Yoshino, T, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_58kok5gvtea2un9haum0204noo